Drug details

Cyramza (ramucirumab solution for intravenous infusion)

type of Antineoplastics, VEGF Inhibitor

Cyramza (ramucirumab) is a recombinant human IgG1 monoclonal antibody used a single-agent is for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

This drug may have the following side effects:

• headache
• diarrhea
• nosebleed
• high blood pressure (hypertension)
• intestinal obstruction
• low levels of sodium in the blood (hyponatremia)
• low white blood cell count (neutropenia)
• arterial blood clots

The following drugs are related to Cyramza, either as a replacement or used together:

• Krazati (adagrasib tablets)
• Adriamycin PFS (doxorubicin hydrochloride)
• Adrucil (fluorouracil injection)
• Rybrevant (amivantamab-vmjw for injection)
• Ayvakit (avapritinib tablets)
• Tabrecta (capmatinib tablets)
• Cosela (trilaciclib for injection)
• Vizimpro (dacomitinib)
• Taxotere (docetaxel for injection)
• Efudex (fluorouracil)
• Rozlytrek (entrectinib capsules)
• Exkivity (mobocertinib capsules)
• Lytgobi (futibatinib tablets)
• Hepzato (melphalan for injection)
• Lorbrena (lorlatinib tablets)
• Lumakras (sotorasib tablets)
• Qinlock (ripretinib tablets)
• Retevmo (selpercatinib capsules)
• Tepmetko (tepotinib tablets)